26 results on '"Dana L. Swenson"'
Search Results
2. Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms
- Author
-
Hong Vu, Gary Wong, Frederick W. Holtsberg, M. Javad Aman, Sergey Shulenin, Stephanie Sproule, Gaya K. Amarasinghe, Daisy W. Leung, Katie A. Howell, Kelly L. Warfield, Joan B. Geisbert, Dana L. Swenson, Gary P. Kobinger, Sina Bavari, and Thomas W. Geisbert
- Subjects
0301 basic medicine ,030106 microbiology ,Supplement Articles ,ZMapp ,Antibodies, Viral ,medicine.disease_cause ,Neutralization ,03 medical and health sciences ,Immune system ,medicine ,Animals ,Immunology and Allergy ,Ebola Vaccines ,Glycoproteins ,Ebola virus ,biology ,Vaccination ,Virion ,Hemorrhagic Fever, Ebola ,Hydrogen-Ion Concentration ,Virology ,Nucleoprotein ,Macaca fascicularis ,Nucleoproteins ,030104 developmental biology ,Infectious Diseases ,Immunization ,biology.protein ,Antibody ,medicine.drug - Abstract
BACKGROUND: Several vaccine platforms have been successfully evaluated for prevention of Ebola virus (EBOV) disease (EVD) in nonhuman primates and humans. Despite remarkable efficacy by multiple vaccines, the immunological correlates of protection against EVD are incompletely understood. METHODS: We systematically evaluated the antibody response to various EBOV proteins in 79 nonhuman primates vaccinated with various EBOV vaccine platforms. We evaluated the serum immunoglobulin (Ig)G titers against EBOV glycoprotein (GP), the ability of the vaccine-induced antibodies to bind GP at acidic pH or to displace ZMapp, and virus neutralization titers. The correlation of these outcomes with survival from EVD was evaluated by appropriate statistical methods. RESULTS: Irrespective of the vaccine platform, protection from EVD strongly correlated with anti-GP IgG titers. The GP-directed antibody levels required for protection in animals vaccinated with virus-like particles (VLPs) lacking nucleoprotein (NP) was significantly higher than animals immunized with NP-containing VLPs or adenovirus-expressed GP, platforms that induce strong T-cell responses. Furthermore, protective immune responses correlated with anti-GP antibody binding strength at acidic pH, neutralization of GP-expressing pseudovirions, and the ability to displace ZMapp components from GP. CONCLUSIONS: These findings suggest key quantitative and qualitative attributes of antibody response to EVD vaccines as potential correlates of protection.
- Published
- 2018
3. AVI-7288 for Marburg Virus in Nonhuman Primates and Humans
- Author
-
Kelly L. Warfield, Peter Sazani, Jay S. Charleston, Sina Bavari, Edward M. Kaye, Travis K. Warren, Alison E. Heald, Jay B. Saoud, Michael Wong, Lisa S. Welch, Jay Wells, Dana L. Swenson, Mohamed Al-Ibrahim, Patrick L. Iversen, and Diane Berry
- Subjects
Kaplan-Meier Estimate ,Placebo ,Body weight ,Antiviral Agents ,Morpholinos ,Marburg virus ,Pharmacokinetics ,Dose group ,Animals ,Humans ,Medicine ,Marburg Virus Disease ,RNA, Messenger ,Dose-Response Relationship, Drug ,biology ,business.industry ,General Medicine ,Marburgvirus ,biology.organism_classification ,Virology ,Nucleoprotein ,Disease Models, Animal ,Macaca fascicularis ,Dose–response relationship ,RNA, Viral ,business - Abstract
AVI-7288 is a phosphorodiamidate morpholino oligomer with positive charges that targets the viral messenger RNA that encodes Marburg virus (MARV) nucleoprotein. Its safety in humans is undetermined.We assessed the efficacy of AVI-7288 in a series of studies involving a lethal challenge with MARV in nonhuman primates. The safety of AVI-7288 was evaluated in a randomized, multiple-ascending-dose study in which 40 healthy humans (8 humans per dose group) received 14 once-daily infusions of AVI-7288 (1 mg, 4 mg, 8 mg, 12 mg, or 16 mg per kilogram of body weight) or placebo, in a 3:1 ratio. We estimated the protective dose in humans by comparing pharmacokinetic variables in infected nonhuman primates, uninfected nonhuman primates, and uninfected humans.Survival in infected nonhuman primates was dose-dependent, with survival rates of 0%, 30%, 59%, 87%, 100%, and 100% among monkeys treated with 0 mg, 3.75 mg, 7.5 mg, 15 mg, 20 mg, and 30 mg of AVI-7288 per kilogram, respectively (P0.001 with the use of the log-rank test for the comparison of survival across groups). No safety concern was identified at doses up to 16 mg per kilogram per day in humans. No serious adverse events were reported. Drug exposure (the area under the curve) was dose-dependent in both nonhuman primates and humans; drug clearance was independent of dose but was higher in nonhuman primates than in humans. The protective dose in humans was initially estimated, on the basis of exposure, to be 9.6 mg per kilogram per day (95% confidence interval, 6.6 to 12.5) for 14 days. Monte Carlo simulations supported a dose of 11 mg per kilogram per day to match the geometric mean protective exposure in nonhuman primates.This study shows that, on the basis of efficacy in nonhuman primates and pharmacokinetic data in humans, AVI-7288 has potential as postexposure prophylaxis for MARV infection in humans. (Funded by the Department of Defense; ClinicalTrials.gov number, NCT01566877.).
- Published
- 2015
4. Advanced antisense therapies for postexposure protection against lethal filovirus infections
- Author
-
Travis K. Warren, Dana L. Swenson, Nicole L. Garza, Jay Wells, Dan V. Mourich, Lian Dong, Kelly L. Warfield, Kelly S Donner, Donald K. Nichols, Patrick L. Iversen, Stacy Crumley, Sina Bavari, and Sean A. Van Tongeren
- Subjects
Primates ,viruses ,Highly pathogenic ,ZMapp ,Biology ,General Biochemistry, Genetics and Molecular Biology ,Viral hemorrhagic fever ,Microbiology ,Marburg virus ,Filoviridae Infections ,medicine ,Animals ,Humans ,Marburg Virus Disease ,Vaccines, Synthetic ,Phosphorodiamidate Morpholino Oligomers ,Viral Vaccines ,General Medicine ,Hemorrhagic Fever, Ebola ,Ebolavirus ,medicine.disease ,Macaca mulatta ,Virology ,Marburgvirus ,Safety ,Zaire Ebola Virus ,medicine.drug - Abstract
Currently, no vaccines or therapeutics are licensed to counter Ebola or Marburg viruses, highly pathogenic filoviruses that are causative agents of viral hemorrhagic fever. Here we show that administration of positively charged phosphorodiamidate morpholino oligomers (PMOplus), delivered by various dosing strategies initiated 30–60 min after infection, protects >60% of rhesus monkeys against lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeys against Lake Victoria Marburg virus (MARV) infection. PMOplus may be useful for treating these and other highly pathogenic viruses in humans.
- Published
- 2010
5. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses
- Author
-
Sadie S. Coberley, D. A. Alves, Sina Bavari, Tom Larsen, Dana L. Swenson, and Kelly L. Warfield
- Subjects
Virosomes ,Guinea Pigs ,Molecular Sequence Data ,Immunology ,Heterologous ,Viral Plaque Assay ,Antibodies, Viral ,medicine.disease_cause ,Marburg virus ,VP40 ,Virus-like particle ,Immunity ,Drug Discovery ,medicine ,Animals ,Marburg Virus Disease ,Amino Acid Sequence ,Viremia ,Antigens, Viral ,Pharmacology ,Viral matrix protein ,Ebola virus ,biology ,Animal Structures ,Viral Vaccines ,Survival Analysis ,Virology ,Macaca fascicularis ,Marburgvirus ,Vaccines, Inactivated ,biology.protein ,Molecular Medicine ,Antibody ,Sequence Alignment - Abstract
Virus-like particle (VLP)-based vaccines have the advantage of being morphologically and antigenically similar to the live virus from which they are derived. Expression of the glycoprotein and VP40 matrix protein from Lake Victoria marburgvirus (MARV) results in spontaneous production of VLPs in mammalian cells. Guinea pigs vaccinated with Marburg virus VLPs (mVLPs) or inactivated MARV (iMARV) develop homologous humoral and T-cell responses and are completely protected from a lethal homologous MARV challenge.To determine whether mVLPs based on the Musoke (aka Lake Victoria) isolate of MARV could broadly protect against diverse isolates of MARV, guinea pigs were vaccinated with mVLPs or iMARV-Musoke and challenged with MARV-Musoke, -Ravn or -Ci67.Prior to challenge, the mVLP- and iMARV-vaccinated guinea pigs had high levels of homologous MARV-Musoke and heterologous MARV-Ravn and -Ci67 antibodies. The Musoke-based mVLPs and iMARV vaccines provided complete protection in guinea pigs against viremia, viral replication and pathological changes in tissues, and lethal disease following challenge with MARV-Musoke, -Ravn or -Ci67. Guinea pigs vaccinated with RIBI adjuvant alone and infected with guinea pig-adapted MARV-Musoke, -Ravn or -Ci67 had histopathologic findings similar to those seen in the nonhuman primate model for MARV infection. Based on the strong protection observed in guinea pigs, we next vaccinated cynomolgus macaques with Musoke-based mVLPs and showed the VLP-vaccinated monkeys were broadly protected against three isolates of MARV (Musoke, Ravn and Ci67).Musoke mVLPs are effective at inducing broad heterologous immunity and protection against multiple MARV isolates.
- Published
- 2008
6. Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections
- Author
-
John Y. Dong, William D. Pratt, Danher Wang, Kelly L. Warfield, Dana L. Swenson, Jan Woraratanadharm, Min Luo, and David H. Holman
- Subjects
Microbiology (medical) ,viruses ,Genetic Vectors ,Clinical Biochemistry ,Immunology ,Filoviridae ,medicine.disease_cause ,Adenoviridae ,Marburg virus ,Marburg virus disease ,medicine ,Animals ,Humans ,Immunology and Allergy ,Marburg Virus Disease ,Ebola Vaccines ,Antigens, Viral ,Ebola virus ,biology ,Ebola vaccine ,Viral Vaccines ,Hemorrhagic Fever, Ebola ,Vaccine Research ,Ebolavirus ,biology.organism_classification ,Marburgvirus ,Bioterrorism ,Virology ,Vaccination ,Macaca fascicularis ,Hemorrhagic Fevers - Abstract
Filoviruses (Ebola and Marburg viruses) are among the deadliest viruses known to mankind, with mortality rates nearing 90%. These pathogens are highly infectious through contact with infected body fluids and can be easily aerosolized. Additionally, there are currently no licensed vaccines available to prevent filovirus outbreaks. Their high mortality rates and infectious capabilities when aerosolized and the lack of licensed vaccines available to prevent such infectious make Ebola and Marburg viruses serious bioterrorism threats, placing them both on the category A list of bioterrorism agents. Here we describe a panfilovirus vaccine based on a complex adenovirus (CAdVax) technology that expresses multiple antigens from five different filoviruses de novo. Vaccination of nonhuman primates demonstrated 100% protection against infection by two species of Ebola virus and three Marburg virus subtypes, each administered at 1,000 times the lethal dose. This study indicates the feasibility of vaccination against all current filovirus threats in the event of natural hemorrhagic fever outbreak or biological attack.
- Published
- 2008
7. Ebola Virus Inactivation with Preservation of Antigenic and Structural Integrity by a Photoinducible Alkylating Agent
- Author
-
Sofi Ibrahim, M. Javad Aman, Warren V. Kalina, Mathias Viard, Yossef Raviv, Kelly L. Warfield, Gene G. Olinger, Xiaoli Chi, Dana L. Swenson, Robert Blumenthal, Mohamed Aitichou, and Sina Bavari
- Subjects
Alkylating Agents ,Azides ,Photochemistry ,viruses ,Filoviridae ,medicine.disease_cause ,Antiviral Agents ,Virus ,Epitope ,Microbiology ,Mice ,Viral envelope ,Chlorocebus aethiops ,medicine ,Animals ,Immunology and Allergy ,Mononegavirales ,Antigens, Viral ,Vero Cells ,Infectivity ,Ebola virus ,biology ,Immunogenicity ,Viral Vaccines ,Haplorhini ,Hemorrhagic Fever, Ebola ,Ebolavirus ,biology.organism_classification ,Virology ,Mice, Inbred C57BL ,Disease Models, Animal ,Infectious Diseases ,Democratic Republic of the Congo ,Female - Abstract
Current methods for inactivating filoviruses are limited to high doses of irradiation or formalin treatment, which may cause structural perturbations that are reflected by poor immunogenicity. In this report, we describe a novel inactivation technique for Zaire Ebola virus (ZEBOV) that uses the photoinduced alkylating probe 1,5-iodonaphthylazide (INA). INA is incorporated into lipid bilayers and, when activated by ultraviolet irradiation, alkylates the proteins therein. INA treatment of ZEBOV resulted in the complete loss of infectivity in cells. Results of electron microscopy and virus-capture assays suggested the preservation of conformational surface epitopes. Challenge with 50,000 pfu of INA-inactivated, mouse-adapted ZEBOV did not cause disease or death in mice. A single vaccination with INA-inactivated ZEBOV (equivalent to 5 x 10(4) pfu) protected mice against lethal challenge with 1000 pfu of ZEBOV. INA-inactivated virus induced a protective response in 100% of mice when administered 3 days before challenge. Thus, INA may have significant potential for the development of vaccines and immunotherapeutics for filoviruses and other enveloped viruses.
- Published
- 2007
8. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection
- Author
-
Kelly L. Warfield, Alan L. Schmaljohn, M. Javad Aman, Sina Bavari, Dana L. Swenson, and Diane L. Negley
- Subjects
CD4-Positive T-Lymphocytes ,viruses ,Guinea Pigs ,Filoviridae ,Viral Plaque Assay ,CD8-Positive T-Lymphocytes ,Biology ,Antibodies, Viral ,Vaccines, Attenuated ,Virus ,Microbiology ,Marburg virus ,Virus-like particle ,Neutralization Tests ,Immunity ,Animals ,Marburg Virus Disease ,Lymphocyte Count ,Mononegavirales ,General Veterinary ,General Immunology and Microbiology ,Vaccination ,Public Health, Environmental and Occupational Health ,Antibody titer ,Viral Vaccines ,Ebolavirus ,biology.organism_classification ,Virology ,Microscopy, Electron ,Infectious Diseases ,Marburgvirus ,Antibody Formation ,Molecular Medicine - Abstract
Ongoing outbreaks of filoviruses in Africa and concerns about their use in bioterrorism attacks have led to intense efforts to find safe and effective vaccines to prevent the high mortality associated with these viruses. We previously reported the generation of virus-like particles (VLPs) for the filoviruses, Marburg (MARV) and Ebola (EBOV) virus, and that vaccinating mice with Ebola VLPs (eVLPs) results in complete survival from a lethal EBOV challenge. The objective of this study was to determine the efficacy of Marburg VLPs (mVLPs) as a potential vaccine against lethal MARV infection in a guinea pig model. Guinea pigs vaccinated with mVLPs or inactivated MARV developed MARV-specific antibody titers, as tested by ELISA or plaque-reduction and neutralization assays and were completely protected from a MARV challenge over 2000 LD50. While eVLP vaccination induced high EBOV-specific antibody responses, it did not cross-protect against MARV challenge in guinea pigs. Vaccination with mVLP or eVLP induced proliferative responses in vitro only upon re-exposure to the homologous antigen and this recall proliferative response was dependent on the presence of CD4+ T cells. Taken together with our previous work, these findings suggest that VLPs are a promising vaccine candidate for the deadly filovirus infections.
- Published
- 2004
9. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein
- Author
-
Dana L. Swenson, Alan L. Schmaljohn, Kelly L. Warfield, Thomas Larsen, Sina Bavari, M. Javad Aman, Michael Hevey, and Kathleen A. Kuehl
- Subjects
Microbiology (medical) ,viruses ,Immunology ,Filoviridae ,Antibodies, Viral ,Transfection ,Microbiology ,Virus ,Cell Line ,Viral Matrix Proteins ,Marburg virus ,Mice ,VP40 ,Viral Envelope Proteins ,Virus-like particle ,Animals ,Immunology and Allergy ,Mononegavirales ,Cells, Cultured ,Mice, Inbred BALB C ,Membrane Glycoproteins ,Viral matrix protein ,biology ,Virion ,General Medicine ,biology.organism_classification ,Marburgvirus ,Immunohistochemistry ,Virology ,Microscopy, Electron ,Infectious Diseases ,Female - Abstract
Marburg virus (MARV), the causative agent of a severe hemorrhagic fever, has a characteristic filamentous morphology. Here we report that co-expression of MARV glycoprotein and matrix protein (VP40) in mammalian cells leads to spontaneous budding of filamentous particles strikingly similar to wild-type MARV. In addition, these particles elicit an immune response in BALB/c mice. The generation of non-replicating Marburg virus-like particles (VLPs) should significantly facilitate the research on molecular mechanisms of MARV assembly and release. Furthermore, VLPs may be an excellent vaccine candidate against Marburg infection.
- Published
- 2004
10. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase
- Author
-
Bing Chen, Ernesto J. Muñoz-Elías, Dana L. Swenson, William R. Jacobs, David G. Russell, John D. McKinney, James C. Sacchettini, Kerstin Höner zu Bentrup, Wal Tsing Chan, and Andras Miczak
- Subjects
Cellular immunity ,Tuberculosis ,Recombinant Fusion Proteins ,Glyoxylate cycle ,Virulence ,Microbiology ,Mycobacterium tuberculosis ,Mice ,Immune system ,Bacterial Proteins ,medicine ,Animals ,Lung ,Pathogen ,Mice, Knockout ,Mice, Inbred BALB C ,Multidisciplinary ,biology ,Macrophages ,Fatty Acids ,Isocitrate lyase ,Macrophage Activation ,medicine.disease ,biology.organism_classification ,Isocitrate Lyase ,Mice, Inbred C57BL ,Mutagenesis ,Immunology - Abstract
Mycobacterium tuberculosis claims more human lives each year than any other bacterial pathogen. Infection is maintained in spite of acquired immunity and resists eradication by antimicrobials. Despite an urgent need for new therapies targeting persistent bacteria, our knowledge of bacterial metabolism throughout the course of infection remains rudimentary. Here we report that persistence of M. tuberculosis in mice is facilitated by isocitrate lyase (ICL), an enzyme essential for the metabolism of fatty acids. Disruption of the icl gene attenuated bacterial persistence and virulence in immune-competent mice without affecting bacterial growth during the acute phase of infection. A link between the requirement for ICL and the immune status of the host was established by the restored virulence of delta icl bacteria in interferon-gamma knockout mice. This link was apparent at the level of the infected macrophage: Activation of infected macrophages increased expression of ICL, and the delta icl mutant was markedly attenuated for survival in activated but not resting macrophages. These data suggest that the metabolism of M. tuberculosis in vivo is profoundly influenced by the host response to infection, an observation with important implications for the treatment of chronic tuberculosis.
- Published
- 2000
11. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents
- Author
-
Nichole A. Posten, Sina Bavari, Dominic Esposito, Gene G. Olinger, Julie Costantino, M. Javad Aman, William K. Gillette, Rekha G. Panchal, Ralph F. Hopkins, James L. Hartley, Dana L. Swenson, and Kelly L. Warfield
- Subjects
viruses ,Filoviridae ,Rodentia ,medicine.disease_cause ,Virus Replication ,Virus ,Cell Line ,Mice ,VP40 ,Immune system ,medicine ,Filoviridae Infections ,Immunology and Allergy ,Animals ,Humans ,Marburg Virus Disease ,Mononegavirales ,Ebola virus ,biology ,Immunogenicity ,Dendritic Cells ,Hemorrhagic Fever, Ebola ,biology.organism_classification ,Ebolavirus ,Virology ,Nucleoprotein ,Mice, Inbred C57BL ,Disease Models, Animal ,Infectious Diseases ,Marburgvirus ,Female - Abstract
Background. Virus-like particles (VLPs) of Ebola virus (EBOV) and Marburg virus (MARV) produced in human 293T embryonic kidney cells have been shown to be effective vaccines against filoviral infection. In this study, we explored alternative strategies for production of filovirus-like particle-based vaccines, to accelerate the development process. The goal of this work was to increase the yield of VLPs, while retaining their immunogenic properties. Methods. Ebola and Marburg VLPs (eVLPs and mVLPs, respectively) were generated by use of recombinant baculovirus constructs expressing glycoprotein, VP40 matrix protein, and nucleoprotein from coinfected insect cells. The baculovirus-derived eVLPs and mVLPs were characterized biochemically, and then the immune responses produced by the eVLPs in insect cells were studied further. Results. The baculovirus-derived eVLPs elicited maturation of human myeloid dendritic cells (DCs), indicating their immunogenic properties. Mice vaccinated with insect cell-derived eVLPs generated antibody and cellular responses equivalent to those vaccinated with mammalian 293T cell-derived eVLPs and were protected from EBOV challenge in a dose-dependent manner. Conclusion. Together, these data suggest that filovirus-like particles produced by baculovirus expression systems, which are amenable to large-scale production, are highly immunogenic and are suitable as safe and effective vaccines for the prevention of filoviral infection.
- Published
- 2007
12. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge
- Author
-
Kelly L. Warfield, Sina Bavari, Gene G. Olinger, Dana L. Swenson, Warren V. Kalina, and M. Javad Aman
- Subjects
viruses ,Filoviridae ,medicine.disease_cause ,Antibodies, Viral ,Kidney ,Virus ,Cell Line ,VP40 ,Virus-like particle ,medicine ,Immunology and Allergy ,Animals ,Humans ,Ebola Vaccines ,Mononegavirales ,Ebola virus ,Ebola vaccine ,biology ,Hemorrhagic Fever, Ebola ,biology.organism_classification ,Ebolavirus ,Virology ,Vaccination ,Disease Models, Animal ,Macaca fascicularis ,Infectious Diseases ,Immunology - Abstract
Background. Currently, there are no licensed vaccines or therapeutics for the prevention or treatment of infection by the highly lethal filoviruses, Ebola virus (EBOV) and Marburg virus (MARV), in humans. We previously had demonstrated the protective efficacy of virus-like particle (VLP)-based vaccines against EBOV and MARV infection in rodents. Methods. To determine the efficacy of vaccination with Ebola VLPs (eVLPs) in nonhuman primates, we vaccinated cynomolgus macaques with eVLPs containing EBOV glycoprotein (GP), nucleoprotein (NP), and VP40 matrix protein and challenged the macaques with 1000 pfu of EBOV. Results. Serum samples from the eVLP-vaccinated nonhuman primates demonstrated EBOV-specific antibody titers, as measured by enzyme-linked immunosorbent assay, complement-mediated lysis assay, and antibody-dependent cell-mediated cytotoxicity assay. CD44 + T cells from eVLP-vaccinated macaques but not from a naive macaque responded with vigorous production of tumor necrosis factor-a after EBOV-peptide stimulation. All 5 eVLP-vaccinated monkeys survived challenge without clinical or laboratory signs of EBOV infection, whereas the control animal died of infection. Conclusion. On the basis of safety and efficacy, eVLPs represent a promising filovirus vaccine for use in humans.
- Published
- 2007
13. NKp30-dependent cytolysis of filovirus-infected human dendritic cells
- Author
-
M. Javad Aman, Gordon Ruthel, Sina Bavari, Catharine M. Bosio, Kelly L. Warfield, Claudette L. Fuller, and Dana L. Swenson
- Subjects
Cytotoxicity, Immunologic ,Pore Forming Cytotoxic Proteins ,Fas Ligand Protein ,medicine.medical_treatment ,Immunology ,Microbiology ,Interleukin 21 ,Virology ,medicine ,Humans ,Receptors, Immunologic ,Cells, Cultured ,Innate immune system ,Membrane Glycoproteins ,Natural Cytotoxicity Triggering Receptor 3 ,biology ,Cell Death ,Natural Cytotoxicity Triggering Receptor 2 ,Natural Cytotoxicity Triggering Receptor 1 ,Perforin ,Virion ,Dendritic Cells ,Filoviridae ,Flow Cytometry ,Killer Cells, Natural ,Cytolysis ,Cytokine ,Mutation ,biology.protein ,Cytokines ,K562 Cells ,K562 cells - Abstract
Understanding how protective innate immune responses are generated is crucial to defeating highly lethal emerging pathogens. Accumulating evidence suggests that potent innate immune responses are tightly linked to control of Ebola and Marburg filoviral infections. Here, we report that unlike authentic or inactivated Ebola and Marburg, filovirus-derived virus-like particles directly activated human natural killer (NK) cells in vitro, evidenced by pro-inflammatory cytokine production and enhanced cytolysis of permissive target cells. Further, we observed perforin- and CD95L-mediated cytolysis of filovirus-infected human dendritic cells (DCs), primary targets of filovirus infection, by autologous NK cells. Gene expression knock-down studies directly linked NK cell lysis of infected DCs to upregulation of the natural cytotoxicity receptor, NKp30. These results are the first to propose a role for NK cells in the clearance of infected DCs and the potential involvement of NKp30-mediated cytolysis in control of viral infection in vivo. Further elucidation of the biology of NK cell activation, specifically natural cytotoxicity receptors like NKp30 and NKp46, promises to aid our understanding of microbial pathology.
- Published
- 2007
14. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice
- Author
-
Dana L. Swenson, Kelly L. Warfield, Jeffery L. Smith, Sina Bavari, Patrick L. Iversen, Sven Enterlein, David A. Stein, Elke Mühlberger, C. Scott Gamble, and Andrew D. Kroeker
- Subjects
government.form_of_government ,Morpholines ,Filoviridae ,medicine.disease_cause ,Virus Replication ,Antiviral Agents ,Virus ,Mice ,Viral Proteins ,Chlorocebus aethiops ,medicine ,Animals ,Pharmacology (medical) ,Viral Regulatory and Accessory Proteins ,Mononegavirales ,Vero Cells ,Pharmacology ,Ebolavirus ,Antisense therapy ,Ebola virus ,biology ,Dose-Response Relationship, Drug ,Reverse Transcriptase Polymerase Chain Reaction ,RNA ,Hemorrhagic Fever, Ebola ,biology.organism_classification ,Virology ,Mice, Inbred C57BL ,Kinetics ,Infectious Diseases ,Viral replication ,government ,RNA, Viral ,Female ,Peptides - Abstract
Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.
- Published
- 2006
15. Viral Hemorrhagic Fevers
- Author
-
Emily M. Deal, Dana L. Swenson, Nancy Jaax, Tom Larsen, Kelly L. Warfield, and Sina Bavari
- Subjects
Hemorrhagic Fevers ,business.industry ,Medicine ,business ,Virology - Published
- 2005
16. Filovirus-like particles as vaccines and discovery tools
- Author
-
Kelly L. Warfield, Dana L. Swenson, Gretchen L. Demmin, and Sina Bavari
- Subjects
viruses ,Immunology ,Filoviridae ,medicine.disease_cause ,Virus ,Microbiology ,Marburg virus ,VP40 ,Drug Discovery ,medicine ,Filoviridae Infections ,Animals ,Humans ,Technology, Pharmaceutical ,Pharmacology ,Ebola virus ,biology ,Immunogenicity ,virus diseases ,Viral Vaccines ,biology.organism_classification ,Virology ,Vaccination ,Hemorrhagic Fevers ,Molecular Medicine - Abstract
Ebola and Marburg viruses are members of the family Filoviridae, which cause severe hemorrhagic fevers in humans. Filovirus outbreaks have been sporadic, with mortality rates currently ranging from 30 to 90%. Unfortunately, there is no efficacious human therapy or vaccine available to treat disease caused by either Ebola or Marburg virus infection. Expression of the filovirus matrix protein, VP40, is sufficient to drive spontaneous production and release of virus-like particles (VLPs) that resemble the distinctively filamentous infectious virions. The addition of other filovirus proteins, including virion proteins (VP)24, 30 and 35 and glycoprotein, increases the efficiency of VLP production and results in particles containing multiple filovirus antigens. Vaccination with Ebola or Marburg VLPs containing glycoprotein and VP40 completely protects rodents from lethal challenge with the homologous virus. These candidate vaccines are currently being tested for immunogenicity and efficacy in nonhuman primates. Furthermore, the Ebola and Marburg VLPs are being used as a surrogate model to further understand the filovirus life cycle, with the goal of developing rationally designed vaccines and therapeutics. Thus, in addition to their use as a vaccine, VLPs are currently being used as tools to learn lessons about filovirus pathogenesis, immunology, replication and assembly requirements.
- Published
- 2005
17. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection
- Author
-
Kelly L. Warfield, Emily M. Deal, Mary Kate Hart, Dana L. Swenson, Gene G. Olinger, Michael Bailey, Diane L. Negley, and Sina Bavari
- Subjects
Male ,T cell ,Immunology ,Molecular Sequence Data ,Epitopes, T-Lymphocyte ,Biology ,CD8-Positive T-Lymphocytes ,medicine.disease_cause ,Antibodies, Viral ,Viral Matrix Proteins ,Interferon-gamma ,Mice ,VP40 ,Adjuvants, Immunologic ,Viral Envelope Proteins ,Immunity ,medicine ,Immunology and Allergy ,Cytotoxic T cell ,Animals ,Amino Acid Sequence ,Cells, Cultured ,Mice, Knockout ,Mice, Inbred BALB C ,Ebola virus ,Virion ,Viral Vaccines ,Hemorrhagic Fever, Ebola ,Saponins ,Ebolavirus ,Virology ,Vaccination ,Mice, Inbred C57BL ,medicine.anatomical_structure ,Immunization ,Vaccines, Subunit ,Female ,CD8 - Abstract
Ebola virus (EBOV)-like particles (eVLP), composed of the EBOV glycoprotein and matrix viral protein (VP)40 with a lipid membrane, are a highly efficacious method of immunization against EBOV infection. The exact requirements for immunity against EBOV infection are poorly defined at this time. The goal of this work was to determine the requirements for EBOV immunity following eVLP vaccination. Vaccination of BALB/c or C57BL/6 mice with eVLPs in conjunction with QS-21 adjuvant resulted in mixed IgG subclass responses, a Th1-like memory cytokine response, and protection from lethal EBOV challenge. Further, this vaccination schedule led to the generation of both CD4+ and CD8+ IFN-γ+ T cells recognizing specific peptides within glycoprotein and VP40. The transfer of both serum and splenocytes, but not serum or splenocytes alone, from eVLP-vaccinated mice conferred protection against lethal EBOV infection in these studies. B cells were required for eVLP-mediated immunity to EBOV because B cell-deficient mice vaccinated with eVLPs were not protected from lethal EBOV challenge. We also found that CD8+, but not CD4+, T cells are absolutely required for eVLP-mediated protection against EBOV infection. Further, eVLP-induced protective mechanisms were perforin-independent, but IFN-γ-dependent. Taken together, both EBOV-specific humoral and cytotoxic CD8+ T cell responses are critical to mediate protection against filoviruses following eVLP vaccination.
- Published
- 2005
18. Isolation of Mycobacterium tuberculosis mutants defective in the arrest of phagosome maturation
- Author
-
Dana L. Swenson, Carren Wang, Jennifer Anderson, Sylvie Alonso, Kevin Pethe, and David G. Russell
- Subjects
Multidisciplinary ,Genotype ,Endosome ,Macrophages ,Mycobacterium tuberculosis ,Biology ,Hydrogen-Ion Concentration ,Biological Sciences ,biology.organism_classification ,Microbiology ,Cell biology ,Microscopy, Electron ,Phenotype ,Spectrometry, Fluorescence ,Phagosomes ,Phagosome maturation ,Mutation ,Macrophage ,Colloids ,Gold ,Bacteria ,Biogenesis ,Genetic screen ,Phagosome - Abstract
Mycobacterium tuberculosisresides within the phagocytes of its host. It ensures its continued survival through arresting the normal maturation of its phagosome, which is retained within the early endosomal system of the macrophage. Although individual bacterial components have been shown to modulate phagosome biogenesis, the mechanism(s) active in live, intact bacteria remain elusive. We have developed a genetic screen that facilitates the isolation of mutants defective in arresting the maturation of their phagosomes. Macrophages were incubated with iron-dextran that was chased into lysosomes. The cells were subsequently infected withM. tuberculosisfrom a library of transposon-mutagenized bacteria. After four rounds of enrichment, the majority of mutants isolated were unable to prevent acidification of their phagosomes and were attenuated for intracellular survival. The genes affected range in function from those with no known homologues to putative transporters and lipid synthesis enzymes. Further characterization of these bacteria is needed. In addition to clarifying the processes active in modulation of phagosome biogenesis byM. tuberculosis, this screen may be applicable to other pathogens that restrict the maturation of their phagosome.
- Published
- 2004
19. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections
- Author
-
M. Javad Aman, Dana L. Swenson, Alan L. Schmaljohn, Kelly L. Warfield, Diane L. Negley, and Sina Bavari
- Subjects
viruses ,Guinea Pigs ,Filoviridae ,medicine.disease_cause ,Antibodies, Viral ,Microbiology ,Marburg virus ,Ebola Hemorrhagic Fever ,VP40 ,Virus-like particle ,medicine ,Animals ,Viremia ,Mononegavirales ,Glycoproteins ,Ebola virus ,General Veterinary ,General Immunology and Microbiology ,biology ,Viral Core Proteins ,Vaccination ,Public Health, Environmental and Occupational Health ,Virion ,virus diseases ,Viral Vaccines ,biology.organism_classification ,Ebolavirus ,Virology ,Infectious Diseases ,Nucleoproteins ,Marburgvirus ,Molecular Medicine - Abstract
A safe and effective pan-filovirus vaccine is highly desirable since the filoviruses Ebola virus (EBOV) and Marburg virus (MARV) cause highly lethal disease typified by unimpeded viral replication and severe hemorrhagic fever. Previously, we showed that expression of the homologous glycoprotein (GP) and matrix protein VP40 from a single filovirus, either EBOV or MARV, resulted in formation of wild-type virus-like particles (VLPs) in mammalian cells. When used as a vaccine, the wild-type VLPs protected from homologous filovirus challenge. The aim of this work was to generate a multi-agent vaccine that would simultaneously protect against multiple and diverse members of the Filoviridae family. Our initial approach was to construct hybrid VLPs containing heterologous viral proteins, of EBOV and MARV, and test the efficacy of the hybrid VLPs in a guinea pig model. Our data indicate that vaccination with GP was required and sufficient to protect against a homologous filovirus challenge, as heterologous wild-type VLPs or hybrid VLPs that did not contain the homologous GP failed to protect. Alternately, we vaccinated guinea pigs with a mixture of wild-type Ebola and Marburg VLPs. Vaccination with a single dose of the multivalent VLP vaccine elicited strong immune responses to both viruses and protected animals against EBOV and MARV challenge. This work provides a critical foundation towards the development of a pan-filovirus vaccine that is safe and effective for use in primates and humans.
- Published
- 2004
20. The gene fimU affects expression of Salmonella typhimurium type 1 fimbriae and is related to the Escherichia coli tRNA gene argU
- Author
-
Steven Clegg, Erich W. Six, Kyoung-Jin Kim, and Dana L. Swenson
- Subjects
Salmonella typhimurium ,Agglutination ,Restriction Mapping ,Mutant ,Fimbria ,Biology ,medicine.disease_cause ,Microbiology ,Lysogen ,Lysogenic cycle ,Gene cluster ,Escherichia coli ,Genetics ,medicine ,Lysogeny ,Molecular Biology ,Regulation of gene expression ,Gene Expression Regulation, Bacterial ,biochemical phenomena, metabolism, and nutrition ,Lambda phage ,biology.organism_classification ,Bacteriophage lambda ,Genes, Bacterial ,Fimbriae, Bacterial ,Multigene Family ,bacteria ,Salmonella Phages - Abstract
The gene fimU, located on a recombinant plasmid carrying the Salmonella typhimurium type 1 fimbrial gene cluster is closely related to the Escherichia coli tRNA gene argU. The fimU gene complements an E. coli argU mutant that is a P2 lysogen, thereby allowing the phage P4 to grow in this strain but preventing the growth of phage lambda. In addition, fimU was shown to be involved in fimbrial expression since transformants of the E. coli argU mutant could produce fimbriae only in the presence of fimU but not in its absence, whereas in an E. coli argU+ strain fimbriation did not require the fimU gene.
- Published
- 1994
21. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis
- Author
-
Kerstin Höner zu Bentrup, Andras Miczak, David G. Russell, and Dana L. Swenson
- Subjects
IDH1 ,Physiology and Metabolism ,Glyoxylate cycle ,Palmitates ,Succinic Acid ,Acetates ,Microbiology ,Gene Expression Regulation, Enzymologic ,Corynebacterium glutamicum ,Open Reading Frames ,Rhodococcus fascians ,Bacterial Proteins ,Escherichia coli ,Isocitrate lyase activity ,Cloning, Molecular ,Molecular Biology ,biology ,Isocitrate lyase ,Mycobacterium tuberculosis ,Hydrogen-Ion Concentration ,biology.organism_classification ,Isocitrate Lyase ,Recombinant Proteins ,Isoenzymes ,Open reading frame ,Kinetics ,Biochemistry ,Mycobacterium ,Mycobacterium avium - Abstract
Analysis by two-dimensional gel electrophoresis revealed that Mycobacterium avium expresses several proteins unique to an intracellular infection. One abundant protein with an apparent molecular mass of 50 kDa was isolated, and the N-terminal sequence was determined. It matches a sequence in the M. tuberculosis database (Sanger) with similarity to the enzyme isocitrate lyase of both Corynebacterium glutamicum and Rhodococcus fascians . Only marginal similarity was observed between this open reading frame (ORF) (termed icl ) and a second distinct ORF (named aceA ) which exhibits a low similarity to other isocitrate lyases. Both ORFs can be found as distinct genes in the various mycobacterial databases recently published. Isocitrate lyase is a key enzyme in the glyoxylate cycle and is essential as an anapleurotic enzyme for growth on acetate and certain fatty acids as carbon source. In this study we express and purify Icl, as well as AceA proteins, and show that both exhibit isocitrate lyase activity. Various known inhibitors for isocitrate lyase were effective. Furthermore, we present evidence that in both M. avium and M. tuberculosis the production and activity of the isocitrate lyase is enhanced under minimal growth conditions when supplemented with acetate or palmitate.
- Published
- 1999
22. The frequency of fim genes among Salmonella serovars
- Author
-
D.C. Old, Steven Clegg, and Dana L. Swenson
- Subjects
Salmonella typhimurium ,Salmonella ,Fimbria ,Molecular cloning ,Biology ,medicine.disease_cause ,Microbiology ,Bacterial Adhesion ,Transformation, Genetic ,Bacterial Proteins ,Complementary DNA ,Gene cluster ,medicine ,Escherichia coli ,Serotyping ,Adhesins, Bacterial ,Gene ,Southern blot ,Genetics ,Chromosome Mapping ,Genetic Variation ,Gene Expression Regulation, Bacterial ,Blotting, Southern ,Infectious Diseases ,Hemagglutinins ,Fimbriae, Bacterial ,DNA Probes - Abstract
Salmonella serovars were examined for the presence of fim gene sequences using specific DNA probes. All strains, regardless of their ability to express surface-associated fimbriae, retain a considerable amount of DNA homologous to the gene probes used. The phenotypically non-fimbriate FIRN and non-FIRN strains of S. typhimurium retain detectable amounts of fim gene sequences and, therefore, may not be genotypically non-fimbriate. The MS adhesin can be expressed by type 2 fimbriate bacteria when they are transformed with discrete regions of the fim gene cluster. However, this conversion to a hemagglutinating phenotype is not associated with a small region of DNA. Therefore, the inability of type 2 fimbria-producing strains of Salmonella to mediate hemagglutination does not appear to be due to a small deletion in a single fim gene.
- Published
- 1991
23. Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers
- Author
-
Donald K. Nichols, M. Javad Aman, Robert E. Blouch, Kelly L. Warfield, Gene G. Olinger, Patrick L. Iversen, William D. Pratt, David A. Stein, Dana L. Swenson, and Sina Bavari
- Subjects
lcsh:Immunologic diseases. Allergy ,Primates ,Male ,Morpholino ,Morpholines ,government.form_of_government ,Immunology ,Biology ,Virus Replication ,medicine.disease_cause ,Microbiology ,Morpholinos ,Marburg virus ,Mice ,Viral Proteins ,Virology ,Genetics ,Antisense Elements (Genetics) ,medicine ,Animals ,Viral Regulatory and Accessory Proteins ,lcsh:QH301-705.5 ,Molecular Biology ,Ebolavirus ,Antisense therapy ,Ebola virus ,Cell Biology ,Mus (Mouse) ,Hemorrhagic Fever, Ebola ,Macaca mulatta ,In Vitro ,Mice, Inbred C57BL ,Hemorrhagic Fevers ,Infectious Diseases ,lcsh:Biology (General) ,Viral replication ,Protein Biosynthesis ,Viruses ,government ,RNA, Viral ,Female ,Parasitology ,lcsh:RC581-607 ,Research Article ,Biotechnology - Abstract
The filoviruses Marburg virus and Ebola virus (EBOV) quickly outpace host immune responses and cause hemorrhagic fever, resulting in case fatality rates as high as 90% in humans and nearly 100% in nonhuman primates. The development of an effective therapeutic for EBOV is a daunting public health challenge and is hampered by a paucity of knowledge regarding filovirus pathogenesis. This report describes a successful strategy for interfering with EBOV infection using antisense phosphorodiamidate morpholino oligomers (PMOs). A combination of EBOV-specific PMOs targeting sequences of viral mRNAs for the viral proteins (VPs) VP24, VP35, and RNA polymerase L protected rodents in both pre- and post-exposure therapeutic regimens. In a prophylactic proof-of-principal trial, the PMOs also protected 75% of rhesus macaques from lethal EBOV infection. The work described here may contribute to development of designer, “druggable” countermeasures for filoviruses and other microbial pathogens., Synopsis Ebola virus (EBOV) causes a highly lethal hemorrhagic fever that results in up to 50%–90% mortality in humans. There are currently no available vaccines or therapeutics to treat EBOV infection. To date, multiple pre- and post-exposure therapeutic strategies, primarily focused on bolstering the host immune response or inhibiting viral replication, have been undertaken with limited success. Here, Bavari and colleagues report the development of a successful therapeutic regimen for EBOV infection based on antisense phosphorodiamidate morpholino oligomers (PMOs). PMOs are a subclass of chemically modified antisense oligonucleotides that interfere with the translation of viral mRNA, thus inhibiting viral amplification. Using a cell-free translation system, a cell-based assay, and survival studies in rodents, we identified several efficacious EBOV-specific PMOs. Further, prophylactic administration of a combination of three EBOV-specific PMOs specifically targeting VP24, VP35, and the viral polymerase L protected rhesus macaques from lethal EBOV infection. This is the first successful antiviral intervention against filoviruses in nonhuman primates. These findings may serve as the basis for a new strategy to quickly develop virus-specific therapies in defense against known, emerging, and genetically engineered bioterrorism threats.
- Published
- 2006
24. Restriction fragment length polymorphisms associated with abnormal lipid levels in an adolescent population
- Author
-
Jackie L. Bristow, Dana L. Swenson, Julia Lee, Richard A. Anderson, and Trudy L. Burns
- Subjects
Genetic Markers ,Male ,medicine.medical_specialty ,Apolipoprotein B ,Adolescent ,Population ,Internal medicine ,medicine ,Humans ,Allele ,education ,Genetics ,Hypertriglyceridemia ,education.field_of_study ,Polymorphism, Genetic ,biology ,Haplotype ,Cholesterol, HDL ,Restriction Site Polymorphism ,Minor allele frequency ,Endocrinology ,Genetic marker ,biology.protein ,lipids (amino acids, peptides, and proteins) ,Female ,Restriction fragment length polymorphism ,Cardiology and Cardiovascular Medicine ,Apoproteins - Abstract
The association of restriction fragment length polymorphism genetic markers at the apolipoprotein AI-CIII-AIV gene locus with lipid and lipoprotein levels was evaluated in subsets of the 666 Caucasian students from the junior high school (11-14 years old) population of Muscatine, Iowa. Male students whose leukocyte DNA had an uncommon haplotype consisting of the minor allele of a SacI restriction site polymorphism (S2) in combination with the more common allele of an MspI site variation (M1) had significantly lower levels of high density lipoprotein (HDL)-cholesterol (P less than 0.05) when compared to a random sample of males; these levels were stable over a 2-year follow-up. The minor allele of an XmnI restriction site polymorphism (X2) was more frequent in females with triglyceride levels in the upper decile of the age and gender-specific triglyceride distribution than in normotriglyceridemic females (0.10 less than P less than 0.15) and triglyceride levels were higher in random sample females with an X2 allele than in X1 homozygotes (P less than 0.10). These results suggest that alleles of the known apolipoprotein genes (AI, CIII, AIV) at this locus or closely linked gene sequences may have major effects on lipid levels in members of the general population.
- Published
- 1989
25. Involvement of Vacuolar Protein Sorting Pathway in Ebola Virus Release Independent of TSG101 Interaction
- Author
-
Gordon Ruthel, George Kallstrom, Lynn S. Silvestri, Patrick L. Iversen, Dana L. Swenson, Kelly L. Warfield, M. Javad Aman, Timothy Nelle, and Sina Bavari
- Subjects
Endosome ,Filoviridae ,macromolecular substances ,medicine.disease_cause ,Kidney ,Cell Line ,Viral Proteins ,VP40 ,medicine ,Immunology and Allergy ,TSG101 ,Humans ,Mononegavirales ,DNA Primers ,Vacuolar protein sorting ,Viral matrix protein ,Ebola virus ,Microscopy, Confocal ,biology ,Endosomal Sorting Complexes Required for Transport ,Cell Membrane ,biology.organism_classification ,Ebolavirus ,Virology ,Cell biology ,DNA-Binding Proteins ,Protein Transport ,Infectious Diseases ,Oligodeoxyribonucleotides ,Mutagenesis ,Vacuoles ,Transcription Factors - Abstract
Budding of Ebola virus (EBOV) particles from the plasma membrane of infected cells requires viral and host proteins. EBOV virus matrix protein VP40 recruits TSG101, an ESCRT-1 (host cell endosomal sorting complex required for transport-1) complex protein in the vacuolar protein sorting (vps) pathway, to the plasma membrane during budding. Involvement of other vps proteins in EBOV budding has not been established. Therefore, we used VP40 deletion analysis, virus-like particle-release assays, and confocal microscopy to investigate the potential role of ESCRT-1 proteins VPS4, VPS28, and VPS37B in EBOV budding. We found that VP40 could redirect each protein from endosomes to the cell surface independently of TSG101 interaction. A lack of VPS4 adenosine triphosphatase activity reduced budding by up to 80%. Inhibition of VPS4 gene expression by use of phosphorodiamidite morpholino antisense oligonucleotides protected mice from lethal EBOV infection. These data show that EBOV can use vps proteins independently of TSG101 for budding and reveal VPS4 as a potential target for filovirus therapeutics.
- Full Text
- View/download PDF
26. Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection
- Author
-
Sina Bavari, Gordon Ruthel, Robert E. Blouch, Jed N. Hassinger, Travis K. Warren, Hong M. Moulton, Dwight D. Weller, Patrick L. Iversen, Kelly L. Warfield, Candace E. Lovejoy, and Dana L. Swenson
- Subjects
Male ,Morpholino ,Morpholines ,Filoviridae ,medicine.disease_cause ,Virus Replication ,Antiviral Agents ,Virus ,Mice ,Structure-Activity Relationship ,Chlorocebus aethiops ,medicine ,Animals ,Humans ,Pharmacology (medical) ,Mononegavirales ,Gene ,Vero Cells ,Pharmacology ,Ebola virus ,biology ,Dose-Response Relationship, Drug ,Hemorrhagic Fever, Ebola ,Oligonucleotides, Antisense ,biology.organism_classification ,Ebolavirus ,Virology ,In vitro ,Antisense RNA ,Mice, Inbred C57BL ,Disease Models, Animal ,Infectious Diseases ,Treatment Outcome ,Female ,Rabbits - Abstract
Phosphorodiamidate morpholino oligomers (PMOs) are uncharged nucleic acid-like molecules designed to inactivate the expression of specific genes via the antisense-based steric hindrance of mRNA translation. PMOs have been successful at knocking out viral gene expression and replication in the case of acute viral infections in animal models and have been well tolerated in human clinical trials. We propose that antisense PMOs represent a promising class of therapeutic agents that may be useful for combating filoviral infections. We have previously shown that mice treated with a PMO whose sequence is complementary to a region spanning the start codon of VP24 mRNA were protected against lethal Ebola virus challenge. In the present study, we report on the abilities of two additional VP24-specific PMOs to reduce the cell-free translation of a VP24 reporter, to inhibit the in vitro replication of Ebola virus, and to protect mice against lethal challenge when the PMOs are delivered prior to infection. Additionally, structure-activity relationship evaluations were conducted to assess the enhancement of antiviral efficacy associated with PMO chemical modifications that included conjugation with peptides of various lengths and compositions, positioning of conjugated peptides to either the 5′ or the 3′ terminus, and the conferring of charge modifications by the addition of piperazine moieties. Conjugation with arginine-rich peptides greatly enhanced the antiviral efficacy of VP24-specific PMOs in infected cells and mice during lethal Ebola virus challenge.
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.